Reports
Sale
Global Antisense and RNAi Therapeutics Market Size, Share, Analysis, Forecast: By Technology: RNA Interference, siRNA, miRNA, Antisense RNA; By Indication: Oncology, Cardiovascular Diseases, Respiratory Disorders, Renal Disease. Others; By Route of Administration; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Antisense and RNAi Therapeutics Market Outlook
The global antisense and rNAi therapeutics market size attained a value of USD 1.71 billion in 2023 driven by intensive study of gene functioning for disease management, through the use of malfunctioning gene and controlling its gene expression. The market is anticipated to grow at a CAGR of 8.5% during the forecast period of 2024-2032 to attain a value of USD 3.56 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentation
Antisense and RNAi therapeutics make particular and highly effective gene silencing possible. Antisense technology offers a chance to manipulate the expression of gene and thus, it is regarded as an efficient therapy for targeting ribonucleic acids (RNA). It is widely used for oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Antisense and RNAi therapeutics industry can be further divided based on:
- Technology
- RNA interference
- SiRNA
- MiRNA
- Antisense RNA
- Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intra-dermal Injections
- Intraperitoneal Injections
- Topical Delivery
The EMR report looks into the regional antisense and RNAi therapeutics markets like the North America, Latin America, Europe, Middle East and Africa, and Asia Pacific.
Market Analysis
The global antisense and RNAi therapeutics industry is being driven by intensive study of gene functioning for disease management, through the use of malfunctioning gene and controlling its gene expression. The market is further driven by various collaborations taking place between pharmaceutical companies and contract research organisations, working to enhance drug delivery.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
The report presents a detailed analysis of the following key players in the global antisense and RNAi therapeutics industry, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- OliX Pharmaceuticals Inc.
- Sanofi S.A, SAN (EPA)
- GlaxoSmithKline, GSK (LON)
- Ionis Pharmaceuticals
- Benitec Biopharma Ltd
- Silence Therapeutics Plc
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Indication |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Antisense and RNAi Therapeutics Market Overview
3.1 Global Antisense and RNAi Therapeutics Market Historical Value (2017-2023)
3.2 Global Antisense and RNAi Therapeutics Market Forecast Value (2024-2032)
4 Global Antisense and RNAi Therapeutics Market Landscape
4.1 Global Antisense and RNAi Therapeutics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Antisense and RNAi Therapeutics Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Indication
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by End User
5 Global Antisense and RNAi Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Antisense and RNAi Therapeutics Market Segmentation
6.1 Global Antisense and RNAi Therapeutics Market by Technology
6.1.1 Market Overview
6.1.2 RNA Interference
6.1.3 siRNA
6.1.4 miRNA
6.1.5 Antisense RNA
6.2 Global Antisense and RNAi Therapeutics Market by Indication
6.2.1 Market Overview
6.2.2 Oncology
6.2.3 Cardiovascular Disease
6.2.4 Respiratory Disorders
6.2.5 Renal Disease
6.2.6 Neurodegenerative Disorders
6.2.7 Genetic Disorders
6.2.8 Infectious Disease
6.2.9 Others
6.3 Global Antisense and RNAi Therapeutics Market by Route of Administration
6.3.1 Market Overview
6.3.2 Pulmonary Delivery
6.3.3 Intravenous Injections
6.3.4 Intra-dermal Injections
6.3.5 Intraperitoneal Injections
6.3.6 Topical Delivery
6.3.7 Others
6.4 Global Antisense and RNAi Therapeutics Market by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Specialty Clinics
6.4.4 Others
6.5 Global Antisense and RNAi Therapeutics Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Antisense and RNAi Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Antisense and RNAi Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Antisense and RNAi Therapeutics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Antisense and RNAi Therapeutics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Antisense and RNAi Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 OliX Pharmaceuticals, Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Sanofi S.A. SAN (EPA)
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 GlaxoSmithKline Plc GSK (LON)
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Ionis Pharmaceuticals, Inc.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Benitec Biopharma Inc.,
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Silence Therapeutics Plc
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Astellas Pharma Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Alnylam Pharmaceuticals, Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 MEDLINE INDUSTRIES
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Dicerna Pharmaceuticals
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Tekmira Pharmaceuticals
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Cenix BioScience
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Sirnaomics
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Arrowhead Pharmaceuticals
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
18 Global Antisense and RNAi Therapeutics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
Globally, antisense and RNAi therapeutics market reached a value of USD 1.71 billion in 2023.
The market is projected to expand at a CAGR of 8.5% from 2023 to 2031, growing to USD 3.56 billion by 2032.
The major industry drivers are intensive study of gene functioning for disease management, through the use of malfunctioning gene, and controlling its gene expression.
The key trends in the market are various collaborations taking place between pharmaceutical companies and contract research organisations, working to enhance drug delivery.
What are the major regional markets of antisense and RNAi therapeutics, according to the EMR report?
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The technology types include RNA interference, siRNA, miRNA, and antisense RNA.
The application sectors include oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, and infectious diseases, among others.
The routes of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, and topical delivery, among others.
The major players in the industry are OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceutical, Benitec Biopharma Ltd, Silence Therapeutics Plc, Others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER